Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $22.10 | Total: $110.50 |
| 1 | 10 | $18.72 | Total: $187.20 |
| 1 | 25 | $15.86 | Total: $396.50 |
| 1 | 50 | $13.52 | Total: $676.00 |
| 1 | 100 | $11.70 | Total: $1,170.00 |
Overview
Flurocitabine HCl is a fluorinated anhydride analog of cytarabine, which is partially hydrolyzed in vivo to two active antitumor substances (arabinosyl-fluorouracil (ara-FC) and arabinosyl-fluorouracil (ara-FU)).Flurocitabine HCl has demonstrated antitumor activity in phase I studies in acute leukemia and solid tumors.
Chemical Properties
| Molecular Formula | C9H11ClFN3O4 |
| Molecular Weight | 279.65 |
| CAS Numbers | 40505-45-1 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | O[C@H]1[C@]2([C@](N3C(O2)=NC(=N)C(F)=C3)(O[C@@H]1CO)[H])[H].Cl |
Storage and Handling
0C Short Term, -20C Long Term
References
Alberto P, et al. Phase II study of anhydro-ara-5-fluorocytidine in adenocarcinoma of gastrointestinal tract, epidermoid carcinoma of lung, head and neck, breast carcinoma and small cell anaplastic carcinoma of lung. A study report of the E.O.R.T.C. early clinical trial cooperative group. Eur J Cancer [1965]. 1978;14[2] 195-201.